Key facts
- Trethera’s last known valuation is $13.1M (Apr 2019).
- It has raised $35.0M across 7 recorded rounds; the latest was Seed Round ($250K) in Apr 2025.
- Notable investors include National Institutes of Health, Libertatis Ergo Holding (LEH), LifeSciences@Work, National Cancer Institute, National Eye Institute — 7 tracked in total.
- Trethera has filed 8 Form Ds with the SEC since 2016, most recently May 2025 ($250K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Trethera
Funding rounds
7 roundsAbout Trethera
Developer of nucleotide metabolism drugs designed to provide treatment for cancer and autoimmune diseases. The company's drugs are deoxycytidine kinase inhibitor that improves bioavailability and demonstrates anti-tumor activity in combination therapies, enabling patients to avail of drugs that improve treatment efficacy and overcome the limitations of single-agent therapies.
- Sector
- Healthcare
- HQ
- Sherman Oaks, CA, United States
- Founded
- 2015
- Employees
- 9
- Website
- trethera.com/
- Ownership
- Privately Held (backing)
Trethera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trethera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trethera in its N-PORT filings yet. We sweep new filings monthly.